Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys-Reference-Cited by-同舟云学术

Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys

Published:2001-04 Issue:2 Volume:8 Page:343-350
ISSN:0969-9961
Container-title:Neurobiology of Disease
language:en
Short-container-title:Neurobiology of Disease

Author:

Bezard Erwan,Ravenscroft Paula,Gross Christian E.,Crossman Alan R.,Brotchie Jonathan M.

Publisher

Elsevier BV

Subject

Neurology

Reference39 articles.

1. Parkinson's disease: Pathophysiology;Agid;Lancet,1991

2. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing;Alexander;Trends Neurosci.,1990

3. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys;Asselin;Neuroreport,1994

4. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors;Baik;Nature,1995

5. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism;Bezard;Neuroscience,1997

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The roles of connectivity and neuronal phenotype in determining the pattern of α-synuclein pathology in Parkinson's disease;Neurobiology of Disease;2022-06

2. Comprehensive mapping of neurotransmitter networks by MALDI–MS imaging;Nature Methods;2019-09-23

3. State transitions in the substantia nigra reticulata predict the onset of motor deficits in models of progressive dopamine depletion in mice;eLife;2019-03-06

4. Transcriptome responses to reduced dopamine in the Substantia Nigra Pars Compacta reveals a potential protective role for dopamine;2018-11-11

5. The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia;Neuropharmacology;2018-10